ASCO 2021 Lung Recap: Surgical Outcomes & Checkmate 816: Nivolumab in Early Stage NSCLC

ASCO 2021 Lung Recap: Surgical Outcomes & Checkmate 816: Nivolumab in Early Stage NSCLCПодробнее

Checkmate 816: Combining Chemo and Opdivo - ASCO Lung Review 2022Подробнее

CheckMate 816: addressing unanswered questions on surgical outcomes following neoadjuvant chemo-IOПодробнее

2021 ASCO Direct San Francisco | Local Lung Cancer Summary | Dr. Millie DasПодробнее

Event-free survival results from CheckMate 816Подробнее

Upcoming NSCLC trials in 2022: CheckMate 816 & KEYNOTE-091Подробнее

ASCO 2021 Lung Recap: Circulatory Tumor DNAПодробнее

Surgical outcomes from CheckMate 816: NIVO plus chemo vs chemo alone as neoadjuvant treatment fo...Подробнее

Surgical outcomes from the Phase III CheckMate 816 trialПодробнее

CheckMate 816 trial: Nivolumab + platinum-doublet chemotherapy vs chemo as neoadjuvant treatment...Подробнее

Perioperative therapies in NSCLCПодробнее

ASCO 2021 Lung Recap: FDA Analysis of Immunotherapy With or Without Chemo in Adv NSCLC and Low PDL-1Подробнее

Lung cancer trial updates at ASCO 2021Подробнее

Expert Video Report on featured outcomes from novel NSCLC trials @AACR 2022Подробнее

CheckMate 816: what does the data tell us?Подробнее

ASCO 2021 Lung Recap: MYLUNG Consortium: Overall Biomarker TestingПодробнее

The CheckMate 816 Trial: The Success of Adjuvant NSCLC Therapies - Lung Cancer OncTalk 2022Подробнее

Dr. Patrick Forde Discusses 3-Year CheckMate 816 NSCLC Results at ASCO 2023Подробнее

Checkmate 816: Neoadjuvant Nivolumab + Chemotherapy for NSCLC - OncTalk Lung 2023Подробнее